Subcorneal Pustular Dermatosis

Ellis, Francis A.

doi:10.1001/archderm.1958.01560110028003

Cited by 13 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SCPD has been associated with pyoderma gangrenosum 155, 156 , inflammatory bowel disease 148, 149, 157 and IgA monoclonal gammopathy, including IgA myeloma 155, 158, 159 ,. Infectious precipitants including urinary tract infections and upper respiratory infections have also been described 160 . Systemic manifestations including fever, malaise, fatigue and arthralgias are rare in SCPD 149 .…”

Section: Pustular Psoriasis and Clinical Variantsmentioning

confidence: 99%

Autoinflammatory Pustular Neutrophilic Diseases

Naik

Cowen

2013

Dermatologic Clinics

114

View full text Add to dashboard Cite

SYNOPSIS The inflammatory pustular dermatoses constitute a spectrum of non-infectious conditions ranging from localized involvement to generalized disease with associated acute systemic inflammation and multi-organ involvement. Despite the variability in extent and severity of cutaneous presentation, each of these diseases is characterized by non-infectious neutrophilic intra-epidermal microabscesses. Many share systemic findings including fever, elevated inflammatory markers, inflammatory bowel disease and/or osteoarticular involvement, suggesting potential common pathogenic links (Figure 1). The recent discoveries of several genes responsible for heritable pustular diseases have revealed a distinct link between pustular skin disease and regulation of innate immunity. These genetic advances have led to a deeper exploration of common pathways in pustular skin disease and offer the potential for a new era of biologic therapy which targets these shared pathways. This chapter provides a new categorization of inflammatory pustular dermatoses in the context of recent genetic and biologic insights. We will discuss recently-described monogenic diseases with pustular phenotypes, including deficiency of IL-1 receptor antagonist (DIRA), deficiency of the IL-36 receptor antagonist (DITRA), CARD14-associated pustular psoriasis (CAMPS), and pyogenic arthritis, pyoderma gangrenosum, acne (PAPA). We will then discuss how these new genetic advancements may inform how we view previously described pustular diseases, including pustular psoriasis and its clinical variants, with a focus on historical classification by clinical phenotype.

show abstract